HEMOSTATICS

Hemostatics is developing CM-352, a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling hemorrhagic conditions... Hemostatics Pharmaceuticals S.L. is an emerging biotechnology company specialising in the development of a novel antifibrinolytic agent. The Company was created in August 2020 by a highly experienced team who established a strategic partnership and exclusive Licensing for the technology with the "Fundación para la Investigación Médica Aplicada" (FIMA), a not-for-profit foundation managing the "Centro de Investigación Médica Aplicada" (CIMA, University of Navarra), the biomedical research center of the "Clinica Universidad de Navarra", based in Pamplona, Spain... The Hemostatics Team is actively working to complete the preclinical development plan and be ready to transition to Phase 1, while in parallel securing funding.

Also known as: Hemostatics Pharmaceuticals, Hemostatics Pharmaceuticals S.L.